08:41 AM EDT, 08/27/2024 (MT Newswires) -- Soleno Therapeutics ( SLNO ) said Tuesday that the US Food and Drug Administration has accepted a new drug application for its experimental drug, DCCR, to treat Prader-Willi syndrome in certain patients four years of age and older.

The company said the FDA granted priority review for the new drug application and expected a decision by December 27.

In its priority review designation letter, the FDA also stated it plans to hold an advisory committee meeting to discuss the application.

Price: 47.17, Change: +1.04, Percent Change: +2.25